All In Biotech

Investigational drug · Phase 3

ABP 692

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsing-remitting Multiple Sclerosis (RRMS).

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "ABP 692"

First trial start

2025

Jan 13, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ABP 692", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Approved drugs for the same conditions: Multiple sclerosis · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "ABP 692" as an intervention, largest first.

All trials
  • Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Pivotal-lookingActive, not recruiting

    AmgenAmgen (AMGN)

    NCT06700343 · 152 participants · Start Jan 13, 2025 · Primary completion Apr 19, 2027

    Drug: Ocrelizumab (US); Ocrelizumab (EU) and 1 more · For: Relapsing-remitting Multiple Sclerosis (RRMS)

    Sites: Mobile, Alabama; Scottsdale, Arizona; Carlsbad, California · 109 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Relapsing-remitting Multiple Sclerosis (RRMS)

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • IMU-838Vidofludimus calciumPhase 33 trials

    Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

  • BCD-281Phase 31 trial

    Biocad · Relapsing-remitting Multiple Sclerosis (RRMS)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.